alexa
Reach Us +44-1647-403003
DNA-PK, a Pharmacological Target in Cancer Chemotherapy and Radiotherapy? | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Commentary

DNA-PK, a Pharmacological Target in Cancer Chemotherapy and Radiotherapy?

Bernard Salles1*, Patrick Calsou2 and Gladys Mirey1

1INRA, Université de Toulouse III, UMR1331, Toxalim (Research Centre in Food Toxicology), F-31027 Toulouse, France

2CNRS; IPBS (Institut de Pharmacologie et de Biologie Structurale); 205 route de Narbonne, F-31077 Toulouse, France

*Corresponding Author:
Bernard Salles
DVM, PhD, INRA, Université de Toulouse
III, UMR1331, Toxalim (Research Centre in Food Toxicology)
F-31027 Toulouse, France
E-mail: [email protected]

Received Date: October 17, 2011; Accepted Date: December 01, 2011; Published Date: December 03, 2011

Citation: Salles B, Calsou P, Mirey G (2011) DNA-PK, a Pharmacological Target in Cancer Chemotherapy and Radiotherapy? J Cancer Sci Ther S8:001. doi:10.4172/1948-5956.S8-001

Copyright: © 2011 Salles B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

In the search for ways of sensitizing tumor cells to chemotherapy or radiotherapy, the inhibition of DNA repair has recently been proposed as a target of clinical interest. Ionizing radiation, as well as several antitumor drugs, induce the formation of DNA double-strand breaks (DSBs), that are highly damaging to the DNA, leading to cell death and genomic instability. DSBs are mainly repaired by the Non-Homologous End-Joining (NHEJ) process, in which DNA dependent protein kinase (DNA-PK) is the key complex. Consequently, specific DNA-PK inhibitors have been selected and evaluated for sensitizing cells to chemotherapy or radiotherapy. The choice of DNA-PK as a pharmacological target of interest in cancer treatment is discussed.

 

Keywords

Share This Page
Top